Literature DB >> 28839746

The role of near-patient coeliac serology testing in the follow-up of patients with coeliac disease.

D A George1, L L Hui2, D Rattehalli1, T Lovatt1, I Perry1, M Green1, K Robinson1, J R F Walters2, M J Brookes1.   

Abstract

OBJECTIVE: This pilot study was undertaken to assess the validity and effectiveness of near-patient coeliac immunological testing, compared to standard laboratory immunological techniques, used in the context of dietician-led coeliac disease follow-up clinics.
DESIGN: The study was designed in two phases, each assessing the near-patient test and standard laboratory immunological techniques. Phase 1 analysed stored serum samples; Phase 2 analysed whole blood from patients attending the dietician-led coeliac disease clinics.
SETTING: Patients were recruited from New Cross Hospital, Wolverhampton (n=50), and Imperial College London (n=30), between March 2010 and February 2011. PATIENTS: Those with a diagnosis of coeliac disease for greater than 12 months attending dietician-led coeliac disease clinics.
INTERVENTIONS: In addition to whole blood taken for routine analysis, patients required a capillary finger-prick blood sample. MAIN OUTCOME MEASURE: To determine if the whole blood and serum near-patient test results were in correlation with outcomes of standard laboratory evaluation.
RESULTS: Phase 1 demonstrated that the near-patient serum test had a sensitivity of 93.5% (95% CI 0.79% to 0.98%), specificity of 94.9% (0.83% to 0.99%), when compared to standard laboratory ELISA. Phase 2, involving patients whole blood, had a sensitivity of 77.8% (0.45% to 0.93%), and specificity of 100% (0.94% to 1%).
CONCLUSIONS: This pilot study has demonstrated that there appears to be a role for near-patient testing in coeliac disease, but further studies are recommended.

Entities:  

Keywords:  Auto-Antibodies; Celiac Disease; Clinical Decision Making; Dietary Factors; Immunology

Year:  2013        PMID: 28839746      PMCID: PMC5369711          DOI: 10.1136/flgastro-2013-100342

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  13 in total

Review 1.  The histopathology of coeliac disease: time for a standardized report scheme for pathologists.

Authors:  G Oberhuber; G Granditsch; H Vogelsang
Journal:  Eur J Gastroenterol Hepatol       Date:  1999-10       Impact factor: 2.566

2.  Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment.

Authors:  Emilia Sugai; Fabio Nachman; Horacio Váquez; Andrea González; Paola Andrenacci; Andrea Czech; Sonia Niveloni; Roberto Mazure; Edgardo Smecuol; Ana Cabanne; Eduardo Mauriño; Julio Cesar Bai
Journal:  Dig Liver Dis       Date:  2009-08-12       Impact factor: 4.088

3.  Identification of tissue transglutaminase as the autoantigen of celiac disease.

Authors:  W Dieterich; T Ehnis; M Bauer; P Donner; U Volta; E O Riecken; D Schuppan
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

4.  Nuclear fluorescence serum reactivity on monkey oesophagus: a new antibody for the follow-up of coeliac disease?

Authors:  A Picarelli; L Sabbatella; M Di Tola; M Silano; A Nicolussi; S D'Inzeo; A Coppa
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

5.  Immunological diagnosis of childhood coeliac disease: comparison between antigliadin, antireticulin and antiendomysial antibodies.

Authors:  A Lerner; V Kumar; T C Iancu
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

Review 6.  HLA susceptibility genes in celiac disease: genetic mapping and role in pathogenesis.

Authors:  L M Sollid; E Thorsby
Journal:  Gastroenterology       Date:  1993-09       Impact factor: 22.682

7.  Coeliac disease case finding and diet monitoring by point-of-care testing.

Authors:  I R Korponay-Szabó; T Raivio; K Laurila; J Opre; R Király; J B Kovács; K Kaukinen; L Fésüs; M Mäki
Journal:  Aliment Pharmacol Ther       Date:  2005-10-15       Impact factor: 8.171

8.  Looking for celiac disease: diagnostic accuracy of two rapid commercial assays.

Authors:  Gregor Nemec; Alessandro Ventura; Martelossi Stefano; Grazia Di Leo; Valentina Baldas; Alberto Tommasini; Fortunato Ferrara; Andrea Taddio; Angelo Città; Daniele Sblattero; Roberto Marzari; Tarcisio Not
Journal:  Am J Gastroenterol       Date:  2006-07       Impact factor: 10.864

9.  Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study.

Authors:  Ilma R Korponay-Szabó; Katalin Szabados; Jánosné Pusztai; Katalin Uhrin; Eva Ludmány; Eva Nemes; Katri Kaukinen; Anikó Kapitány; Lotta Koskinen; Sándor Sipka; Anikó Imre; Markku Mäki
Journal:  BMJ       Date:  2007-12-06

10.  Endomysial antibody: is it the best screening test for coeliac disease?

Authors:  M Ferreira; S L Davies; M Butler; D Scott; M Clark; P Kumar
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

View more
  3 in total

1.  The Role of an IgA/IgG-Deamidated Gliadin Peptide Point-of-Care Test in Predicting Persistent Villous Atrophy in Patients With Celiac Disease on a Gluten-Free Diet.

Authors:  Michelle S Lau; Peter D Mooney; William L White; Michael A Rees; Simon H Wong; Matthew Kurien; Nick Trott; Daniel A Leffler; Marios Hadjivassiliou; David S Sanders
Journal:  Am J Gastroenterol       Date:  2017-10-10       Impact factor: 10.864

2.  A point-of-care test for facing the burden of undiagnosed celiac disease in the Mediterranean area: a pragmatic design study.

Authors:  Stefano Costa; Luca Astarita; Mongi Ben-Hariz; Giovanni Currò; Jernej Dolinsek; Aydan Kansu; Giuseppe Magazzu'; Stefania Marvaso; Dusanka Micetic-Turku; Salvatore Pellegrino; Giuseppe Primavera; Pasqualino Rossi; Andrea Smarrazzo; Francesca Tucci; Carmela Arcidiaco; Luigi Greco
Journal:  BMC Gastroenterol       Date:  2014-12-18       Impact factor: 3.067

Review 3.  Spinning straw into gold: description of a disruptive rheumatology research platform inspired by the COVID-19 pandemic.

Authors:  S W Tas; G J Wolbink; L Boekel; F Hooijberg; E H Vogelzang; P L Klarenbeek; W H Bos
Journal:  Arthritis Res Ther       Date:  2021-08-05       Impact factor: 5.156

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.